Aytu BioPharma, Inc. (AYTU) Balance Sheet
AYTU balance sheet, FY2026
June 30, 2026 · U.S. dollars$105.0M assets = $69.7M liabilities + $35.3M equity
Both columns are drawn to the same scale: what AYTU owns equals what it owes plus shareholders’ equity. Hover a block for its value.
AYTU financial health
Descriptive bands, not a rating. Fiscal FY2026.
AYTU balance sheet trends, FY2017–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $15.0MFY2017 | $105.0MFY2026 | +24.1%/yr | |
| Total liabilities | $11.0MFY2017 | $69.7MFY2026 | +22.8%/yr | |
| Shareholders’ equity | $4.0MFY2017 | $35.3MFY2026 | +27.4%/yr | |
| Cash & short-term investments | $802,328FY2017 | $26.3MFY2026 | +47.4%/yr | |
| Total debt | $12.5MFY2020 | $18.1MFY2026 | +6.4%/yr | |
| Net cash (debt) | $35.6MFY2020 | $8.2MFY2026 | −$27.4M | |
| Working capital | −$581,906FY2017 | $7.1MFY2026 | +$7.7M | |
| Book value per share | $11.78FY2023 | $2.86FY2026 | −37.6%/yr | |
| Current ratio | 0.84FY2017 | 1.13FY2026 | +0.29 | |
| Debt / equity | 0.13FY2020 | 0.51FY2026 | +0.38 | |
| Shares outstanding | 3.3MFY2023 | 12.3MFY2026 | +54.5%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
AYTU assets
AYTU liabilities and equity
AYTU debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
AYTU balance sheet
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $26.3M | $31.0M | $20.0M | $23.0M | $19.4M | $49.6M | $48.1M | $11.0M | $7.0M | $802,328 |
| Cash & equivalents | $26.3M | $31.0M | $20.0M | $23.0M | $19.4M | $49.6M | $48.1M | $11.0M | $7.0M | $802,328 |
| Short-term investments | — | — | — | — | — | — | — | — | $100,000 | $0 |
| Receivables | $22.8M | $31.2M | $23.5M | $28.9M | $21.7M | $28.2M | $5.2M | $1.7M | $578,782 | $528,039 |
| Inventory | $6.9M | $11.4M | $12.1M | $12.0M | $10.8M | $16.3M | $10.0M | $1.4M | $1.3M | $1.3M |
| Other current assets | $5.8M | $5.6M | $6.2M | $8.9M | $8.0M | $11.1M | $11.7M | $1.2M | $540,009 | $385,974 |
| Total current assets | $61.8M | $79.2M | $61.9M | $72.8M | $59.9M | $105.2M | $75.0M | $15.4M | $9.5M | $3.0M |
| Property, plant & equipment (net) | $1.2M | $1.6M | $1.5M | $3.9M | $6.3M | $8.7M | $892,609 | $203,733 | $219,000 | $647,254 |
| Goodwill & intangible assets | $41.4M | $42.2M | $52.5M | $59.0M | $136.4M | $151.3M | $76.9M | $19.1M | $11.4M | $11.3M |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $601,000 | $1.2M | $3.0M | $2.2M | $0 | $465,000 | $32,981 | $2,200 | $4,716 | $2,888 |
| Total assets | $105.0M | $124.2M | $118.9M | $137.8M | $137.6M | $265.7M | $152.8M | $34.7M | $21.1M | $15.0M |
| Liabilities | ||||||||||
| Accounts payable | $11.3M | $10.6M | $10.3M | $13.5M | $11.0M | $19.3M | $11.8M | $2.1M | $2.1M | $2.2M |
| Short-term debt | $8.2M | $11.1M | $5.0M | $8.7M | $3.9M | $25.5M | $1.3M | — | — | — |
| Deferred revenue | — | — | $38.6M | $46.8M | $57.2M | $57.2M | $339,336 | — | — | — |
| Total current liabilities | $54.7M | $63.1M | $62.2M | $69.0M | $64.4M | $109.4M | $28.3M | $5.4M | $3.4M | $3.6M |
| Long-term debt | $9.1M | $10.9M | $10.9M | $14.7M | $14.3M | $180,000 | $11.2M | $0 | $0 | $0 |
| Lease obligations | — | — | — | — | — | $3.6M | $1.0M | — | — | — |
| Other long-term liabilities | $6.0M | $31.3M | $18.0M | $14.8M | $14.6M | $18.5M | $18.3M | $22.3M | $4.2M | $7.4M |
| Total liabilities | $69.7M | $105.2M | $91.1M | $98.5M | $93.3M | $128.1M | $57.8M | $27.6M | $7.6M | $11.0M |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $1,000 | $1,000 | $1,000 | $1,000 | $4,000 | $3,000 | $12,584 | $1,754 | $179 | $82 |
| Retained earnings (deficit) | −$347.8M | −$333.5M | −$320.0M | −$304.1M | −$287.1M | −$178.3M | −$120.0M | −$106.4M | −$79.3M | −$69.1M |
| Accumulated other comprehensive income | — | — | — | — | $0 | $0 | −$484,000 | −$396,000 | $0 | −$246,000 |
| Total shareholders' equity | $35.3M | $19.0M | $27.7M | $39.4M | $44.3M | $137.6M | $95.0M | $7.1M | $13.4M | $4.0M |
| Key figures | ||||||||||
| Total debt | $18.1M | $22.9M | $16.4M | $30.4M | $18.2M | $31.0M | $12.5M | — | — | — |
| Net cash (debt) | $8.2M | $8.0M | $3.6M | −$7.4M | $1.2M | $18.7M | $35.6M | — | — | — |
| Working capital | $7.1M | $16.1M | −$337,000 | $3.8M | −$4.5M | −$4.2M | $46.7M | $10.1M | $6.1M | −$581,906 |
| Tangible book value | −$6.1M | −$23.2M | −$24.7M | −$19.6M | −$92.1M | −$13.7M | $18.1M | −$12.0M | $2.1M | −$7.3M |
| Book value per share | $2.86 | $3.02 | $5.00 | $11.78 | — | — | — | — | — | — |
| Shares outstanding | 12.3M | 6.3M | 5.5M | 3.3M | — | — | — | — | — | — |
| Current ratio | 1.13 | 1.26 | 0.99 | 1.06 | 0.93 | 0.96 | 2.65 | 2.87 | 2.79 | 0.84 |
| Quick ratio | 0.90 | 0.98 | 0.70 | 0.75 | 0.64 | 0.71 | 1.88 | 2.38 | 2.24 | 0.37 |
| Debt / equity | 0.51 | 1.21 | 0.59 | 0.77 | 0.41 | 0.23 | 0.13 | — | — | — |
| Equity / assets | 33.6% | 15.3% | 23.3% | 28.6% | 32.2% | 51.8% | 62.2% | 20.4% | 63.7% | 26.7% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $26.3M | $26.7M | $30.0M | $32.6M | $31.0M | $18.2M | $20.4M | $20.1M | $20.0M | $19.8M | $19.5M | $20.0M |
| Cash & equivalents | $26.3M | $26.7M | $30.0M | $32.6M | $31.0M | $18.2M | $20.4M | $20.1M | $20.0M | $19.8M | $19.5M | $20.0M |
| Receivables | $22.8M | $24.5M | $30.9M | $33.2M | $31.2M | $35.8M | $25.4M | $23.2M | $23.5M | $29.9M | $29.4M | $29.9M |
| Inventory | $6.9M | $7.5M | $8.7M | $10.1M | $11.4M | $11.1M | $11.1M | $11.7M | $12.1M | $13.2M | $13.0M | $13.0M |
| Other current assets | $5.8M | $8.7M | $6.6M | $5.2M | $5.6M | $7.5M | $6.2M | $5.7M | $6.2M | $8.3M | $9.4M | $7.8M |
| Total current assets | $61.8M | $67.3M | $76.2M | $81.1M | $79.2M | $72.5M | $63.1M | $60.7M | $61.9M | $71.1M | $71.4M | $70.6M |
| Property, plant & equipment (net) | $1.2M | $1.3M | $1.4M | $1.5M | $1.6M | $1.7M | $1.7M | $1.9M | $1.5M | $2.8M | $3.3M | $4.2M |
| Goodwill & intangible assets | $41.4M | $42.5M | $43.6M | $41.4M | $42.2M | $48.7M | $50.0M | $51.2M | $52.5M | $54.1M | $55.7M | $57.3M |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $601,000 | $556,000 | $738,000 | $939,000 | $1.2M | $1.3M | $1.5M | $2.0M | $3.0M | $889,000 | $907,000 | $772,000 |
| Total assets | $105.0M | $111.7M | $122.0M | $125.0M | $124.2M | $124.2M | $116.2M | $115.8M | $118.9M | $128.9M | $131.2M | $132.9M |
| Liabilities | ||||||||||||
| Accounts payable | $11.3M | $13.2M | $14.3M | $12.3M | $10.6M | $12.0M | $11.7M | $13.5M | $10.3M | $10.5M | $10.5M | $14.5M |
| Short-term debt | $8.2M | $12.5M | $11.1M | $16.7M | $11.1M | $12.0M | $6.1M | $6.6M | $5.0M | $16.7M | $2.4M | $1.3M |
| Deferred revenue | — | — | — | — | — | — | — | — | $38.6M | — | $43.4M | $40.7M |
| Total current liabilities | $54.7M | $60.0M | $65.6M | $66.0M | $63.1M | $70.7M | $64.0M | $61.3M | $62.2M | $83.7M | $64.2M | $65.5M |
| Long-term debt | $9.1M | $9.5M | $10.0M | $10.4M | $10.9M | $9.5M | $10.0M | $10.4M | $10.9M | $0 | $15.0M | $14.8M |
| Lease obligations | — | — | — | — | — | — | — | — | — | $16,000 | — | — |
| Other long-term liabilities | $6.0M | $7.0M | $32.2M | $25.4M | $31.3M | $9.1M | $11.4M | $14.3M | $18.0M | $14.4M | $19.2M | $20.4M |
| Total liabilities | $69.7M | $76.5M | $107.8M | $101.8M | $105.2M | $89.3M | $85.5M | $86.0M | $91.1M | $98.1M | $98.4M | $100.7M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 |
| Retained earnings (deficit) | −$347.8M | −$347.8M | −$342.2M | −$331.6M | −$333.5M | −$313.7M | −$317.7M | −$318.5M | −$320.0M | −$315.4M | −$312.5M | −$312.2M |
| Accumulated other comprehensive income | — | — | — | — | — | — | — | — | — | — | $0 | — |
| Total shareholders' equity | $35.3M | $35.1M | $14.2M | $23.2M | $19.0M | $34.9M | $30.8M | $29.8M | $27.7M | $30.8M | $32.9M | $32.2M |
| Key figures | ||||||||||||
| Total debt | $18.1M | $22.9M | $23.1M | $27.2M | $22.9M | $22.5M | $17.1M | $18.2M | $16.4M | $22.5M | $18.3M | $16.2M |
| Net cash (debt) | $8.2M | $3.8M | $7.0M | $5.5M | $8.0M | −$4.3M | $3.3M | $1.9M | $3.6M | −$2.7M | $1.3M | $3.7M |
| Working capital | $7.1M | $7.4M | $10.7M | $15.1M | $16.1M | $1.8M | −$995,000 | −$514,000 | −$337,000 | −$12.6M | $7.2M | $5.1M |
| Tangible book value | −$6.1M | −$7.3M | −$29.4M | −$18.3M | −$23.2M | −$13.8M | −$19.2M | −$21.4M | −$24.7M | −$23.3M | −$22.9M | −$25.2M |
| Book value per share | $2.86 | $3.34 | $1.41 | $1.19 | $2.79 | $4.25 | $3.63 | $3.28 | $5.00 | $5.57 | $5.95 | $5.87 |
| Shares outstanding | 12.3M | 10.5M | 10.0M | 19.5M | 6.8M | 8.2M | 8.5M | 9.1M | 5.5M | 5.5M | 5.5M | 5.5M |
| Current ratio | 1.13 | 1.12 | 1.16 | 1.23 | 1.26 | 1.03 | 0.98 | 0.99 | 0.99 | 0.85 | 1.11 | 1.08 |
| Quick ratio | 0.90 | 0.85 | 0.93 | 1.00 | 0.98 | 0.76 | 0.72 | 0.71 | 0.70 | 0.59 | 0.76 | 0.76 |
| Debt / equity | 0.51 | 0.65 | 1.62 | 1.17 | 1.21 | 0.65 | 0.56 | 0.61 | 0.59 | 0.73 | 0.56 | 0.50 |
| Equity / assets | 33.6% | 31.5% | 11.6% | 18.5% | 15.3% | 28.1% | 26.5% | 25.7% | 23.3% | 23.9% | 25.0% | 24.2% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed September 22, 2026); data from EODHD.
AYTU financial position
At the end of fiscal 2026 (June 30, 2026), Aytu BioPharma had total assets of $105.0 million (down 15.4% from a year earlier), total liabilities of $69.7 million and shareholders' equity of $35.3 million. It held $26.3 million in cash and short-term investments against $18.1 million of debt, a net cash position of $8.2 million. Its current ratio was 1.13.
Related: AYTU income statement, AYTU cash flow statement, AYTU key metrics. See the AYTU stock overview for the latest quote and news.
AYTU balance sheet FAQ
What are Aytu BioPharma's total assets?
Aytu BioPharma reported total assets of $105.0 million at the end of fiscal 2026 (June 30, 2026), compared with $124.2 million a year earlier.
How much debt does Aytu BioPharma have?
Aytu BioPharma had $18.1 million of total debt at the end of fiscal 2026, including short-term borrowings. Its debt-to-equity ratio was 0.51.
How much cash does Aytu BioPharma have?
Aytu BioPharma held $26.3 million in cash and short-term investments at the end of fiscal 2026; with $18.1 million of debt that is net cash of $8.2 million.
What is Aytu BioPharma's book value?
Aytu BioPharma's shareholders' equity (book value) was $35.3 million at the end of fiscal 2026, or $2.86 per share.
What is Aytu BioPharma's current ratio?
Aytu BioPharma had current assets of $61.8 million and current liabilities of $54.7 million, a current ratio of 1.13 (it can cover its short-term obligations).
How much goodwill does Aytu BioPharma have?
Aytu BioPharma carried $41.4 million of goodwill and intangible assets, 39.4% of total assets, at the end of fiscal 2026.